Antiseizure Medication Switching: Lamotrigine to Oxcarbazepine (Trileptal)
Switching is performed by initiating oxcarbazepine titration while continuing lamotrigine initially, then withdrawing lamotrigine over several weeks as oxcarbazepine reaches a therapeutic dose.[1] During oxcarbazepine titration, close observation and monitoring of the concomitant antiseizure drug(s) are recommended because plasma levels of concomitant antiseizure drugs may change.[1]
Medication Selection Algorithm
Oxcarbazepine is introduced at the standard starting dose for the patient population being treated.[1] Concomitant antiseizure medication withdrawal is paired with oxcarbazepine titration during the overlap period.[1]
Key Evidence Supporting This Recommendation
The oxcarbazepine prescribing information describes a switch strategy using overlap: concomitant antiseizure drugs can be completely withdrawn over 3–6 weeks while oxcarbazepine is titrated to a target daily dose.[1] Close observation and monitoring of concomitant antiseizure drug plasma levels are recommended during oxcarbazepine titration due to potential changes in concomitant drug levels.[1]
Monotherapy vs Combination Therapy
Combination therapy is used during the cross-taper period because oxcarbazepine is titrated upward while lamotrigine is maintained for seizure protection.[1] Monotherapy transition is achieved when lamotrigine is completely withdrawn over 3–6 weeks and oxcarbazepine is at the clinically indicated dose.[1]
Important Clarifications and Nuances
Oxcarbazepine titration is described with dose increases that may occur at approximately weekly intervals, with stated maximum increment limits in the prescribing information.[1] Concomitant antiseizure drug plasma levels may change during titration, so therapeutic monitoring is recommended when applicable.[1]
Initiation Thresholds or Indications
For typical patients, oxcarbazepine is initiated at 600 mg/day in a twice-daily regimen (1,200 mg/day total daily dose) during titration phases described in the prescribing information.[1] The prescribing information also provides specific initiation and titration guidance for special populations such as renal impairment, including initiating at one-half the usual starting dose with slower titration.[1]
Common Pitfalls to Avoid
Abrupt discontinuation of concomitant antiseizure therapy during oxcarbazepine titration is not aligned with the prescribing information strategy that uses overlap and staged withdrawal of concomitant antiseizure drugs over 3–6 weeks.[1] Failure to perform close observation during oxcarbazepine titration is not aligned with prescribing information recommendations.[1]
Targets or Goals of Therapy
The goal is lamotrigine discontinuation over 3–6 weeks while oxcarbazepine is titrated to the clinically indicated maintenance dose.[1] The target oxcarbazepine maintenance dose is determined by clinical response, with maximum titration guidance described in the prescribing information.[1]